Cdx3379-04- A Phase 2, Mutlicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Cdx-3379 In Combination With Cetuximab In Patients With Advanced Head And Neck Squamous Cell Carcinoma
Posted Date: Oct 1, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The goal of this study is to estimate the ORR for the combination of CDX-3379 in combination with cetuximab in patients with cetuximab-resistant advanced HNSCC
Criteria:
To Be Eligible: >18 Years Or Older, Life Expectancy >12 Weeks, Diagnosed With Hnscc, No Prior Malignancy Within 3 Years, Nonpregnant/Nonbreastfeeding
Keywords:
Head And Neck Cancer, Hnscc
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com